> Skip repeated content

Mary Kirkland Center for Lupus Research

Selected Publications

Barr RG, Selinger S, Appel GB, Zuniga R, D'Agati V, Salmon J, Radhakrishnan J. Prognosis in proliferative lupus nephritis: The role of socioeconomic status and race/ethnicity. Nephrol Dial Transplant 2003;18:2039-46.

Berman J, Girardi G, Salmon J. TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol 2005 Jan;174:485-90.

Blank MC, Stefanescu RN, Masuda E, Marti F, King PD, Redecha PB, Wurzburger RJ, Peterson MG, Tanaka S, Pricop L. Decreased transcription of the human FCGR2B gene mediated by the -343 G/C promoter polymorphism and association with systemic lupus erythematosus. Hum Genet 2005 May 14; [Epub ahead of print]

Cinamon G, Matloubian M, Lesneski MJ, Xu Y, Low C, Lu T, Proia RL, Cyster JG. Sphingosine 1-phosphate receptor 1 promotes B cell localization in the splenic marginal zone. Nature Immunol 2004;5:713-20.

Crow MK, Kirou KA. Interferon-alpha in systemic lupus erythematosus. Curr Opin Rheumatol 2004;16:541-7.

Crow MK. Costimulatory molecules and T-cell-B-cell interactions. Rheum Dis Clin North Am 2004;30:175-91, vii-viii.

Crow MK, Kirou KA, Wohlgemuth J. Microarray analysis of interferon-regulated genes in SLE. Autoimmunity 2003;36:481-90.

Crow MK. Type I interferon and autoimmune disease. Autoimmunity 2003;36:445-6.

Crow MK. Interferon-alpha: a new target for therapy in systemic lupus erythematosus? Arthritis Rheum 2003;48:2396-401.

Crow MK, Wohlgemuth J. Microarray analysis of gene expression in lupus. Arthritis Res Ther 2003;5:279-287.

Erkan D, Asherson RA, Espinosa G, Cervera R, Font J, Piette JC, Lockshin MD. Catastrophic Antiphospholipid Syndrome Registry Project Group. Long term outcome of catastrophic antiphospholipid syndrome survivors. Ann Rheum Dis 2003;62:530-3.

Erkan D, Ortel TL, Lockshin MD. Warfarin in antiphospholipid syndrome--time to explore new horizons. J Rheumatol 2005;32:208-12.

Erkan D, Lockshin MD. How much warfarin is enough in APS related thrombosis? Thromb Res 2004;114:435-42.

Fleming SD, Egan RP, Girardi G, Holers VM, Salmon J, Monestier M, Tsokos GC. Anti-phospholipid antibodies restore mesenteric ischemia/reperfusion induced injury in complement receptor CR2/CR1 deficient mice. J Immunol 2004; 173:7055-61.

Georgiev M, Agle LM, Chu JL, Elkon KB, Ashany D. Mature dendritic cells readily break tolerance in normal mice but do not lead to disease expression. Arthritis Rheum 2005;52:225-38.

Girardi G, Berman J, Redecha P, Spruce L, Thurman JM, Kraus D, Hollmann TJ, Casali P, Caroll MC, Wetsel RA, Lambris JD, Holers VM, Salmon JE. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003;112: 1644-54.

Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004 Nov;10(11):1222-6.

Harrison MJ, Childs A, Carson PE. Incidence of undiagnosed sleep apnea in patients scheduled for elective total joint arthroplasty. J Arthroplasty 2003 18:1044-1047.

Herrero C, Hu X, Li WP, Samuels S, Sharif MN, Kotenko S, Ivashkiv LB. Reprogramming of IL-10 activity and signaling by IFN-gamma. J Immunol 2003;171:5034-41.

Herve M, Xu K, Ng YS, Wardemann H, Albesiano E, Messmer BT, Chiorazzi N, Meffre E. Unmutated and mutated chronic lymphocytic leukemia derive from self-reactive B cell precursors despite expressing different antibody reactivity. J Clin Invest 2005 May 2; [Epub ahead of print]

Hu X, Li WP, Meng C, Ivashkiv LB. Inhibition of IFN-gamma signaling by glucocorticoids. J Immunol 2003;170:4833-9

Ivashkiv LB, Hu X. Signaling by STATs. Arthritis Res Ther 2004;6:159-68.

Ivashkiv LB. Type I interferon modulation of cellular responses to cytokines and infectious pathogens: potential role in SLE pathogenesis. Autoimmunity 2003;36:473-9.

Ji J-D, Tassiulas I, Park-Min K-H, Aydin A, Mecklenbrauker I, Tarakhovsky A, Pricop L, Salmon J, Ivashkiv L. Inhibition of IL-10 signaling after Fc Receptor ligation and during rheumatoid arthritis. J Exp Med 2003;197:1573-83.

Karassa FB, Bijl M, Davies KA, Kallenberg CGM, Khamashta MA, Manger K, Michel M, Piette J-C, Salmon JE, Song YW, Tsuchiya N, Yoo D-H, Ioannidis JPA. The role of the Fc?RIIA polymorphism in the antiphospholipid syndrome: an international meta-analysis. Arthritis Rheum 2003;48:1930-38.

Kirou KA, Lee C, George S, Louca K, Papagiannis IG, Peterson MG, Ly N, Woodward RN, Fry KE, Lau AY, Prentice JG, Wohlgemuth JG, Crow MK. Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus. Arthritis Rheum 2004;50:3958-67.

Kirou KA, Lee C, George S, Louca, Peterson, Crow MK. Interferon-alpha pathway activation identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 52:1491-1503, 2005.

Liu S, Cerutti A, Casali P, Crow MK. Ongoing immunoglobulin class switch DNA recombination in lupus B cells: analysis of switch regulatory regions. Autoimmunity 2004;37:431-43.

Liu Y, Masuda E, Blank MC, Kirou KA, Gao X, Park MS, Pricop L. Cytokine-mediated regulation of activating and inhibitory Fc{gamma} receptors in human monocytes. J Leukoc Biol 2005 May;77(5):767-76.

Lo CG, Lu TT, Cyster JG. Integrin dependence of lymphocyte entry into the splenic white pulp. J Exp Med 2003;197:353-61.

Manzi S, Ahearn JM, Salmon JE. New Insights into Complement: A Mediator of Injury and Marker of Disease Activity in SLE. Lupus 2004;13: 298-303.

Meffre E, Schaefer A, Wardemann H, Wilson P, Davis E, Nussenzweig MC. Surrogate light chain expressing human peripheral B cells produce self-reactive antibodies. J Exp Med 2004;199:145-150.

Moorthy LN, Robbins L, Harrison MJ, Peterson MG, Cox N, Onel KB, Lehman TJ. Quality of life in paediatric lupus. Lupus 2004;13:234-40.

Peterson MG, Blake VA, Allegrante JP, Johanson NA, Mancuso CA, Robbins L, Ranawat CS, Charlson ME. A comparison of self-reported hip symptomatology in hip replacement patients and a population-based sample of medicare beneficiaries. Med Sci Monit 2004;10:CR275-CR281.

Roman MJ, Shanker B-A, Davis A, Lockshin MD, Sammaritano L, Simantov R, Crow MK, Schwartz JE, Paget SA, Devereux RB, Salmon JE. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. New Engl J Med 2003;349: 2399-406.

Roman MJ, Devereux RB, Schwartz JE, Lockshin MD, Paget SA, Davis A, Crow MK, Sammaritano L, Levine DM, Shankar BA, Moeller E, Salmon JE. Arterial Stiffness in Chronic Inflammatory Diseases. Hypertension 2005 May 23; [Epub ahead of print]

Ruiz-Irastorza G, Khamashta MA, Gordon C, Lockshin MD, Johns KR, Sammaritano L, Hughes GR. Measuring systemic lupus erythematosus activity during pregnancy: validation of the lupus activity index in pregnancy scale. Arthritis Rheum 2004;51:78-82.

Salmon JE. A non-inflammatory pathway for pregnancy loss: Innate immune activation? J Clin Invest 2004;114: 15-17.

von Scheven E, Lu TT, Emery H, Elder M, Wara D. Thrombosis and pediatric Wegener's granulomatosis: acquired and genetic risk factors for hypercoaguability. Arthritis Rheum 2003;49:862-5.

Samuels J, Ng YS, Coupillaud C, Paget D, Meffre E. Impaired early B cell tolerance in patients with rheumatoid arthritis. J Exp Med 2005 May 16;201(10):1659-67.

Sharif MN, Tassiulas I, Hu Y, Mecklenbrauker I, Tarakhovsky A, Ivashkiv LB. IFN-alpha priming results in a gain of proinflammatory function by IL-10: implications for systemic lupus erythematosus pathogenesis. J Immunol 2004;172:6476-81.

Shen Y, Schlessinger K, Zhu X, Meffre E, Quimby F, Levy DE, Darnell JE, Jr. Essential role of STAT3 in postnatal survival and growth revealed by mice lacking STAT3 serine727 phosphorylation. Mol Cell Biol 2004;24:407-419.

Stefanescu RN, Olferiev M, Liu Y, Pricop L. Inhibitory Fc gamma receptors: from gene to disease. J Clin Immunol 2004;24:315-26.

Tassiulas I, Hu X, Ho H, Kashyap Y, Paik P, Hu Y, Lowell CA, Ivashkiv LB. Amplification of IFN-alpha-induced STAT1 activation and inflammatory function by Syk and ITAM-containing adaptors. Nat Immunol 2004;5:1181-9.

Thurman JM, Kraus DM, Girardi G, Hourcade D, Kang HJ, Royer PA, Giclas P, Salmon J, Gilkeson G, Holers VM. A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice. Molecular Immunol 2004;42: 87-97.

Walker ID, Kujovich JL, Greer IA, Rey E, David M, Salmon JE, Hunt BJ, Zotz RB, Gerhardt A, Scharf JE, Middeldorf S, Martinelli I, Cetin I, Grandone E. The use of LMWH in pregnancies at risk: new evidence or perception? J Thromb Haemost 2005 Apr;3(4):778-93.

Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E*, Nussenzweig MC*. Predominant autoantibody production by early human B cell precursors. Science 2003; 301:1374-77. *These authors contributed equally

Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M; International Society of Nephrology Working Group on the Classification of Lupus Nephritis; Renal Pathology Society Working Group on the Classification of Lupus Nephritis. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004;65:521-30.

Yurasov S, Wardemann H, Hammersen J, Tsuiji M, Meffre E, Pascual V, Nussenzweig MC. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med 2005 Mar 7;201(5):703-11.

Zuniga R, Markowitz GS, Arkachaisri T, Imperatore EA, D'Agati VD, Salmon JE. Identification of IgG subclasses and C-reactive protein in lupus nephritis: The relationship between the composition of immune deposits and Fc?RIIA alleles. Arthritis Rheum 2003;48: 460-70.